News

HDA Media And Political Bulletin – 15 September 2016

Pharmacy leaders warn Government against backsliding on cuts

14 September 2016, National Pharmacy Association

 

Department of Health officials have informed pharmacy stakeholders that following a brief period of negotiations a funding cuts package will be made available in mid-October for implementation from December 2016. Pharmacy leaders have since warned the Government against back-tracking on promises to take time when making these decisions and to keep an open dialogue with the sector going forward. Ian Strachan, the Chairman of the NPA, commented to express his thought that a meaningful dialogue with the sector is the best way forward and urged the Pharmacy Minister, David Mowat, not to backslide on his promises. Sue Sharpe, Chief Executive of the PSNC has said that the pharmacy sector is looking to the Government to take a new approach to these funding cuts.

 

UK EU Life Sciences Transition Programme

14 September 2016, ABPI

 

Following the UK’s decision to leave the EU the ABPI has released a manifesto for a strong life science economy outside of the EU. They believe that at this critical time it is very important that the UK shows it is still open for business. In the coming period of negotiations the UK must secure the future of the pharmaceutical industry and minimise business uncertainty going forwards. The key objective of the programme, being led by the UK EU Life Sciences Steering Group, is to determine the UK as a world-leading life sciences environment outside of the EU.

 

Parliamentary Coverage

 

There is no parliamentary coverage today

 

Full Coverage

Pharmacy leaders warn Government against backsliding on cuts

14 September 2016, National Pharmacy Association

 

Pharmacy leaders today warned the Government against backsliding on its promises, when it emerged that the Department of Health could implement cuts to pharmacy funding within weeks – having earlier promised a re-think.

A letter sent this week by Department of Health officials to pharmacy stakeholder’s states that, after a brief spell of negotiations, a package will be announced in mid-October. Implementation will begin from December.

Yet little more than a week ago, new Pharmacy Minister David Mowat announced he was putting on hold cuts to pharmacies in England and related efficiency measures. He told delegates at the Royal Pharmaceutical Society conference in Birmingham that he would “take time to make the correct decision” and would have an ongoing dialogue with the sector about the way forward.

National Pharmacy Association (NPA) Chairman Ian Strachan said today:

“In what sense is this short stay of execution ‘taking the time to make the right decision’? How is a few weeks’ notice adequate time for the pharmacy sector to prepare for the changes? And in what sense is a brief negotiation behind closed doors the ongoing dialogue we were promised just days ago?

“We urge the Minister to be true to his word. He should take the time to get things right for the sector, right for the NHS and right for patients and communities. He should open a genuine dialogue with the sector about the way forward. To be meaningful, such dialogue must be based on genuinely fresh thinking – it would make no sense to take as a starting point the discredited and universally unpopular proposals of December 2015.

“It will do the Minister great credit to pause and reflect, and not simply wave through the discredited policy proposals he inherited. A genuine and informed review is required.

“To proceed in the hurried manner now suggested would be a flat contradiction of the Government’s promises just days ago. It would be dishonest, because the Minister would be going back on his word. It would be intolerable to the millions of patients who oppose the cuts, and disrespectful to our profession because of the lack of time to prepare. What’s more it would be illogical, at a time when GPs and hospitals are so under pressure, to diminish this vital front line service”.

“We are writing to the Health Secretary and his Ministers, asking for their urgent assurances on this matter.”

Sue Sharpe, Chief Executive of the Pharmaceutical Services Negotiating Committee (PSNC) said:

“We are looking to the government to take a new approach, informed by evidence of the value of the sector to the communities we support. Community pharmacy is willing to develop its service to meet future needs, and we need the government to abandon the ill-informed and damaging proposals.”

 

UK EU Life Sciences Transition Programme

14 September 2016, ABPI

 

Following the result of the EU referendum, the ABPI issued a manifesto for a strong life sciences economy outside the EU.

Leaving the EU will present significant challenges to the stability of the industry in the UK.  But at this critical time, it is vital that we send a strong message that the UK is open for business.

​The roadm​ap for the UK leaving the EU must secure the future of our country’s pharmaceutical industry and minimises business uncertainty; open the UK to the world; and promote innovation for a strong, competitive UK.

The ABPI warmly welcomed the announcement from the former Life Sciences Minister that a UK EU Life Sciences Steering Group would be established between industry and Government to ensure that the industry was in as strong a position as possible as the UK establishes a new relationship with the EU.  This followed the recommendation made by the ABPI in our manifesto document.

The ABPI is now working with the BIA to engage the broad life sciences industry to outline the work needed to create a world-leading life sciences environment in the UK outside of the EU.

The Group will report to the Ministerial Industry Strategy Group (MISG) in September and will provide recommendations and considerations for “how the UK can seize the opportunity to define a new relationship with the EU”.

Objectives

The key objective of the Programme is to determine how to create a world-leading life sciences environment in the UK outside of the EU. This will include:

  • Identifying optimal position for the life sciences sector against potential exit scenarios, and generating ideas for agile approaches to overcome barriers and mitigate risks
  • Identifying opportunities to make the UK domestic landscape as strong and attractive as possible for the life sciences industry
  • Providing options for how the UK can negotiate with the EU and relevant EU life sciences bodies to obtain the optimal outcome for UK and European industry, health systems and patients
  • Ensuring a framework for a continued dialogue between the life science industry and the government on these issues​

Governance and Delivery

The Programme is being led by the UK EU Life Sciences Steering Group, as announced by the former Life Sciences Minister, George Freeman.

The Steering Group will be co-chaired by GlaxoSmithKline’s Chief Executive Sir Andrew Witty, and AstraZeneca’s Chief Executive Pascal Soriot.  The ABPI and BIA are also core members of the group

The UK EU Life Sciences Transition Programme will build on existing preliminary analysis from the ABPI and BIA, with support from the Office for Life Sciences.  A Members Leadership Group (MLG) will provide guidance and leadership to the work for ABPI and BIA.

The Programme will focus on six work streams: fiscal and trade, intellectual property, manufacturing and supply, people, regulation, and research and development.

A diagram detailing the structure of the Programme can be found here ​and a webinar to launch the work schedule can be viewed here​.​

ABHI and BIVDA have been informed and invited to be part of the Programme.  We are also liaising with EFPIA and EuropaBio.

The Group will report to the Ministerial Industry Strategy Group (MISG) in September.

HDA Media And Political Bulletin – 15 September 2016

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?